News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • VRA shows strong momentum and high free-cash-flow yield despite a sub-1x price-to-sales multiple.
  • Recommended swing trade entry at $5.60 with a stop-loss at $4.80.
  • Mid-term target set at $8.50, implying roughly 52% upside in ~45 trading days.
  • Trade framed as a disciplined long exposure for short-term traders.
  • Valuation gap between FCF yield and P/S multiple underpins the trade rationale.
  • News favors risk-on activity in small-cap retail names this hour.

Latest Articles

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio Limited (Nasdaq: YDES) and EG BioMed have introduced an AI-based online cancer risk assessment tool that evaluates individual self-reported health data to generate personalized risk reports for ten major cancer types. This tool integrates with their oncology services and aims to empower users with insights for informed healthcare discussions…

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics announced a virtual key opinion leader event scheduled for October 20, 2026, featuring diabetes experts and patient advocates to discuss challenges in type 1 diabetes, hypoglycemia risk, and the company's phase 3 trial of cadisegliatin, an oral glucokinase activator. The event aims to provide insights into the ongoing CATT1 trial w…

NANO Nuclear Energy Appoints Former Y-12 Leader and Nuclear Fuel Cycle Expert Jennifer Charlton, Ph.D., as Vice President of Fuel Technology to Accelerate Vertical Integration Strategy

NANO Nuclear Energy Appoints Former Y-12 Leader and Nuclear Fuel Cycle Expert Jennifer Charlton, Ph.D., as Vice President of Fuel Technology to Accelerate Vertical Integration Strategy

NANO Nuclear Energy Inc. announced the hiring of Jennifer Charlton, Ph.D., a seasoned nuclear fuel cycle expert and former Y-12 National Security Complex leader, as Vice President of Fuel Technology. This strategic appointment aims to accelerate NANO Nuclear's vertical integration across the nuclear fuel cycle, supporting its advanced micro modular…

Pasqal Reaffirms its Commitment to the EU’s Quantum Ambitions as It Leads Q-PLANET for Neutral-Atom Technologies

Pasqal Reaffirms its Commitment to the EU’s Quantum Ambitions as It Leads Q-PLANET for Neutral-Atom Technologies

Pasqal has taken a leading role in the Q-PLANET consortium, which is funded with €50 million by the EU Chips Joint Undertaking and national authorities. The initiative aims to develop industrial-grade chip components for neutral-atom quantum computing, sensing, and communication over the next three years. This effort supports the European Union's s…

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics announced new formulary agreements that increase access to ZELSUVMI (berdazimer) topical gel, a novel treatment for molluscum contagiosum, to a total of 127 million commercially covered lives plus strong Medicaid coverage. This includes a major Pharmacy Benefit Manager covering 24 million lives without prior authorization and a…

SailPoint Report Finds 79% of Enterprises Run AI Agents in Production, Yet Only 2% Have Deployed Purpose-built Security

SailPoint Report Finds 79% of Enterprises Run AI Agents in Production, Yet Only 2% Have Deployed Purpose-built Security

SailPoint's 2026 Horizons of Identity Security report reveals that while 79% of enterprises have deployed AI agents in production, only 2% have purpose-built identity security controls for them, exposing significant operational and compliance risks. The report emphasizes the urgent need to advance from foundational identity security practices to au…

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent BioPharma announced that its Phase 3 FURVENT clinical trial evaluating firmonertinib monotherapy in first-line treatment of locally advanced or metastatic non-squamous NSCLC patients with EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival by blinded independent central review. Although secondary…

Veea Secures Landmark Smart Community Agreement with La Estadia Community for Agentic Real-time Aware and Secure Community

Veea Secures Landmark Smart Community Agreement with La Estadia Community for Agentic Real-time Aware and Secure Community

Veea Inc. has secured a landmark one-year agreement with La Estadia Community to deploy its SecureConnect platform and Veea Vision AI video analytics across 220 residential properties. The project aims to enhance connectivity, cybersecurity, and resident safety through AI-driven edge computing, marking the first phase of broader expansion opportuni…

authID Announces $2 Million Agreement with the EinStrong Foundation

authID Announces $2 Million Agreement with the EinStrong Foundation

authID announced a $2 million technology licensing and service agreement with the EinStrong Foundation, supporting EinStrong's mission to fight poverty and educational inequality worldwide by using authID's biometric identity verification. EinStrong paid $1 million upfront for technology licensing and committed an additional $1 million for biometri…

Mercury Introduces RES One, a Rugged Edge Server Engineered for Rapid Deployment and Superior Lifecycle Management

Mercury Introduces RES One, a Rugged Edge Server Engineered for Rapid Deployment and Superior Lifecycle Management

Mercury Systems introduced RES One, a next-generation rugged edge server designed for rapid deployment, modular upgrades, and reduced sustainment costs in harsh environments. The platform supports long life cycles needed for military and industrial applications by allowing technology refreshes without complete redesigns, and features advanced secur…

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Odyssey Therapeutics announced that additional results from the induction period of its Phase 2a trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate to severe ulcerative colitis, will be presented orally at the upcoming UEG Week 2026. The company will also host a conference call to discuss these new data, underscoring progress in thei…

Genius Group Recommences Bitcoin Treasury Purchases

Genius Group Recommences Bitcoin Treasury Purchases

Genius Group Limited (NYSE American: GNS) has recommenced its Bitcoin treasury purchases, acquiring 10 Bitcoin for approximately $854,000, marking progress in its $1.2 billion dual treasury capital plan targeting significant investments in Bitcoin and AI assets by FY2031. This move follows a favorable court ruling lifting restrictions on the compan…

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Telomir Pharmaceuticals secured $5.6 million through a private investment in public equity, including a $1.0 million additional investment from billionaire John Paul DeJoria. The funds will support the clinical development of Telomir-Zn, an oral small-molecule epigenetic therapy entering Phase 1/2 trials for advanced triple-negative breast cancer a…

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

PDS Biotechnology Corporation announced a virtual key opinion leader event featuring Dr. Jonathan M. Hernandez to discuss clinical outcomes from the PDS0301 Phase 2 trials targeting advanced liver-associated metastatic colorectal cancer, focusing on patients with immunotherapy-resistant microsatellite stable tumors. PDS0301 is an investigational IL…

Upexi to Participate in Upcoming October Investor Conferences

Upexi to Participate in Upcoming October Investor Conferences

Upexi, Inc., a NASDAQ-listed digital asset treasury company focused on accumulating Solana cryptocurrency and developing consumer brands, announced its Chief Strategy Officer Brian Rudick will participate in multiple investor conferences in October 2026. The company aims to showcase its strategic initiatives in Solana asset acquisition and consumer…